(Q39250831)

10 September 2017

title

Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin (English)

1 reference

10 September 2017

0 references

1 reference

1 reference

1 reference

9

1 reference

10 September 2017

Luca Piacentini

4

0 references

Mara Biasin

object named as

Mara Biasin

2

0 references

Massimo Galli

object named as

Massimo Galli

7

0 references

Fosca Niero

5

object named as

Fosca Niero

1 reference

10 September 2017

Laura Milazzo

1

1 reference

10 September 2017

Nadia Gatti

3

1 reference

10 September 2017

Barbara Zanone Poma

6

1 reference

10 September 2017

Mauro Moroni

8

1 reference

10 September 2017

Agostino Riva

10

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

The American Journal of Gastroenterology

10 September 2017

published in

1 reference

10 September 2017

volume

101

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

399-402

1 reference

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00350.X

10.1111/J.1572-0241.2006.00350.X

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference